RBCL — RBC Life Sciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$2.09m
- $28.27m
Annual income statement for RBC Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2010 December 31st | 2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 28.2 | 28.4 | 25.2 | 25.5 | 28.3 |
| Cost of Revenue | |||||
| Gross Profit | 13.7 | 14.3 | 12.6 | 12 | 15.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 27.1 | 28.5 | 25.6 | 26.1 | 28.9 |
| Operating Profit | 1.04 | -0.071 | -0.464 | -0.625 | -0.625 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 0.891 | -0.211 | -0.59 | -0.736 | -0.721 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.558 | -0.071 | -0.361 | -0.5 | -0.603 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.558 | -0.071 | -0.361 | -0.5 | -0.603 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 0.558 | -0.071 | -0.361 | -0.5 | -0.603 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.025 | -0.003 | -0.292 | -0.225 | -0.272 |
| Dividends per Share |